Stay updated with breaking news from Deb Schrag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scientists have developed a new blood test that detects multiple cancers in patients who have no symptoms. Called the Galleri test, the blood test finds various cancers early enough to warrant necessary treatments and other medical interventions. The breakthrough research was obtained in the Pathfinder study where more than 6,600 people above the age of 50
Cancer doctors, care providers and payers need to get ready for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment. New data supporting the accuracy of multi-cancer early detection (MCED) blood testing (1), presented at the ESMO Congress 2022, have major implications for future cancer care provision, said Fabrice André, ESMO 2022 Scientific Co-Chair.
Adding Multi-Cancer Early Detection (MCED) Screening to Standard of Care Screening More Than Doubled the Number of Cancers Detected 71% of Participants With MCED-Detected Cancers Had Cancer Types
Doctors hail new era for cancer screening as major research shows effectiveness of Galleri test
Please replace the release with the following corrected version. A multimedia asset accompanying this release and paragraph seven have been removed. This press release features multimedia. View the